FindTrial
Sign In

CHILDHOOD PULMONARY TUBERCULOSIS CASES SHOWING RESISTANCE TO ISONIAZID BUT SENSITIVE TO RIFAMPICIN BY CBNAAT

ISONIAZID RESISTANCE IN RIFAMPICIN SENSITIVE PULMONARY TUBERCULOSIS IN CHILDREN AND ADOLESCENTS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/03/032203
Enrollment
70
Registered
2021-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A150- Tuberculosis of lung

Interventions

None listed

Sponsors

MAULANA AZAD MEDICAL COLLEGE AND LOK NAYAK HOSPITALNEW DELHI
Lead Sponsor
CHEST CLINIC LOK NAYAK HOSPITAL NEW DELHI
Collaborator
NEW DELHI TUBERCULOSIS CENTRE NEW DELHI
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: children and adolescents up to 18 years of age with pulmonary tuberculosis sensitive to Rifampicin by CBNAAT

Exclusion criteria

Exclusion criteria: History of taking anti tubercular treatment(ATT)for more than 1 month(re-treatment cases)

Design outcomes

Primary

MeasureTime frame
Proportion of cases showing resistance to Isoniazid among Rifampicin sensitive pulmonary tuberculosis in children and adolescents upto 18 yearsTimepoint: 1year—

Secondary

MeasureTime frame
Proportion of cases showing resistance to Ethambutol and Pyrazinamide among Rifampicin sensitive pulmonary tuberculosis in children and adolescents up to 18 yearsTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Priyanka Das

MAULANA AZAD MEDICAL COLLEGE,LOKNAYAK HOSPITAL,NEW DELHI

doctoranuragagarwal@gmail.com9810409625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026